Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis

Hypertension

Volumn 58, Issue 1, 2011, Pages 93-98

  Antoniades, Charalambos ^a   Demosthenous, Michael ^a   Tousoulis, Dimitris ^a   Antonopoulos, Alexios S ^a   Vlachopoulos, Charalambos ^a   Toutouza, Marina ^b   Marinou, Kyriakoula ^a   Bakogiannis, Constantinos ^a   Mavragani, Kleio ^a   Lazaros, George ^a   Koumallos, Nikolaos ^b   Triantafyllou, Costas ^b   Lymperiadis, Dimitris ^b   Koutsilieris, Michael ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

Author keywords

ADMA; atherosclerosis; coronary artery disease; endothelium; inflammation; interleukin 6

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; METHOTREXATE; N(G),N(G) DIMETHYLARGININE; PLACEBO; SALMONELLOSIS VACCINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW MEDIATED DILATION; HEART HEMODYNAMICS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SALMONELLOSIS; VACCINATION;

ARGININE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; PILOT PROJECTS; PROGNOSIS; VASODILATION;

EID: 79959712024     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.168245     Document Type: Article

References (24)

1. Antoniades C, Antonopoulos AS, Bendall JK, Channon KM. Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr Pharm Des. 2009;15:329-342.
2. Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, Cunnington C, Tousoulis D, Pillai R, Ratnatunga C, Stefanadis C, Channon KM. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J. 2009;30:1142-1150.
3. Sydow K, Hornig B, Arakawa N, Bode-Boger SM, Tsikas D, Munzel T, Boger RH. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med. 2004;9:93-101. (Pubitemid 39406423)
4. Melikian N, Wheatcroft SB, Ogah OS, Murphy C, Chowienczyk PJ, Wierzbicki AS, Sanders TA, Jiang B, Duncan ER, Shah AM, Kearney MT. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. Hypertension. 2007;49:873-877. (Pubitemid 351664208)
5. Juonala M, Viikari JS, Alfthan G, Marniemi J, Kahonen M, Taittonen L, Laitinen T, Raitakari OT. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the Cardiovascular Risk in Young Finns Study. Circulation. 2007;116:1367-1373. (Pubitemid 47417562)
6. Boger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality: an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res. 2009;60:481-487.
7. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Boger SM. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S- adenosylmethionine-dependent methyltransferases. Circ Res. 2000;87: 99-105. (Pubitemid 30616904)
8. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl. 2003;4:33-40. (Pubitemid 38234493)
9. Chirinos JA, David R, Bralley JA, Zea-Diaz H, Munoz-Atahualpa E, Corrales-Medina F, Cuba-Bustinza C, Chirinos-Pacheco J, Medina- Lezama J. Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease: the PREVENCION Study. Hypertension. 2008;52:1051-1059.
10. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies: I-principles. Am J Epidemiol. 1992;135: 1019-1028.
11. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies: III- design options. Am J Epidemiol. 1992;135:1042-1050.
12. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies: II-types of controls. Am J Epidemiol. 1992;135:1029-1041.
13. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, Toutouza M, Stefanadis C. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation. 2005;112:2193-2200. (Pubitemid 41475815)
14. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, Strodter D, Simon BC, Mugge A, Daniel WG, Tillmanns H, Maisch B, Streichert T, Boger RH. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination Investigating the Influence of ADMA Concentration (CARDIAC) Study. Am Heart J. 2006;152:493.e491-493.e498.
15. Wilson A, Shin D, Weatherby C, Harada R, Ng M, Nair N, Kielstein J, Cooke JP. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med. 2010: 267-274.
16. Ardigo D, Stuehlinger M, Franzini L, Valtuena S, Piatti PM, Pachinger O, Reaven GM, Zavaroni I. ADMA is independently related to flow- mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest. 2007;37:263-269. (Pubitemid 46439414)
17. Patel S, Celermajer DS, Bao S. Atherosclerosis-underlying inflammatory mechanisms and clinical implications. Int J Biochem Cell Biol. 2008;40: 576-580.
18. Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007;293:H3227-H3245. (Pubitemid 350230862)
19. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Yamada S, Shoji H, Takeuchi M, Ueda S, Matsui T, Adachi H, Okuda S, Yamagishi S. Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. Pharmacol Res. 2009;60:515-518.
20. Perna M, Roman MJ, Alpert DR, Crow MK, Lockshin MD, Sammaritano L, Devereux RB, Cooke JP, Salmon JE. Relationship of asymmetric dimethylarginine and homocysteine to vascular aging in systemic lupus erythematosus patients. Arthritis Rheum. 62:1718-1722.
21. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino L, Boger R. Asymmetrical dimethylarginine, C-reactive protein and carotid intia thickness in end-stage renal disease. J Am Soc Nephrol. 2002;13: 490-496. (Pubitemid 34106292)
22. Zoccali C, Maas R, Cutrupi S, Pizzini C, Finocchiaro P, Cambareri F, Panuccio V, Mortorano C, Schulze F, Enia G, Tripepi G, Boger R. Asymmetric dimethylarginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transplant. 2007;22:801-806. (Pubitemid 46351688)
23. Guzik TJ, Griendling KK. NADPH oxidases: molecular understanding finally reaching the clinical level? Antioxid Redox Signal. 2009;11: 2365-2370.
24. Kao CC, Bandi V, Guntupalli KK, Wu M, Castillo L, Jahoor F. Arginine, citrulline and nitric oxide metabolism in sepsis. Clin Sci (Lond). 2009; 117:23-30.